Journal profile · Oncology
Annals of Oncology
ISSN 0923-7534 · eISSN 1569-8041 · Oxford University Press · ENGLAND · Monthly · Founded 1990
Annals of Oncology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 76.9; hybrid open access; APC about USD 5,080; median 79 days to acceptance (87 articles, last 24 months); community-reported acceptance: fairly hard; 5,417 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Annals of Oncology is published by Oxford University Press and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies and Cancer Immunotherapy and Biomarkers, together about 28.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
An official Journal of the European Society for Medical Oncology and the official journal of the Japanese Society of Medical OncologyAnnals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.With a large international editorial board of experts who are leaders in their fields, Annals of Oncology aims at delivering the best communication on the fast moving, and continually evolving, global oncology landscape.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Thomas Powles LondonPublisher website
Editorial board by country: 1 in mainland China (about 1%); most named United States 26, Japan 23, Italy 16, United Kingdom 11, Germany 11 (135 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine10.3%
- Colorectal Cancer Treatments and StudiesMedicine9.4%
- Cancer Immunotherapy and BiomarkersMedicine8.7%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology7%
- Cancer Treatment and PharmacologyMedicine6%
- Gastric Cancer Management and OutcomesMedicine5.7%
- Lung Cancer Research StudiesMedicine4.8%
- HER2/EGFR in Cancer ResearchMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 76.9LetPub ·
- Impact factor (publisher)
- 80.4Publisher website ·
- CiteScore 2026-06
- 69.6LetPub ·
- CiteScore (publisher)
- 69.6Publisher website ·
- SJR 2026-06
- 21.72LetPub ·
- SNIP 2026-06
- 12.88LetPub ·
- h-index
- 210LetPub ·
- h-index
- 390OpenAlex ·
- i10-index
- 11,994OpenAlex ·
- 2-year mean citedness
- 1.7OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 38.32%LetPub ·
Volume
- Articles per year
- 120LetPub ·
Articles by year OpenAlex count · 67,795 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 722 | 529 | 367 |
| 2025 | 5,417 | 3,999 | 5,045 |
| 2024 | 4,099 | 4,068 | 11,973 |
| 2023 | 4,297 | 4,283 | 18,323 |
| 2022 | 4,163 | 4,162 | 26,924 |
| 2021 | 3,546 | 3,492 | 33,421 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
79 daysMedian, submission to acceptance · P25–P75 35 days – 155 days
- Acceptance to online
- median 8 days (85 articles)
- Submission to online
- median 92 days
- Sample
- 87 articles with submission and acceptance dates (442 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 2–3 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- Submission to acceptance
- 45 daysPublisher website ·
- Peer review
- Single-anonymous peer reviewPublisher website · model-extracted
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 5,080 / EUR 4,750 / GBP 4,070 / JPY 630,070 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- No page charges
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- ≤ 300 words
- Suggested reviewers
- Optional
- Cover letter
- Required
Article types accepted8, with length limits
- editorialsAnnals of Oncology publishes material in the form of Editorials, Original Articles, Letters to the Editor, Reviews, Special Articles, and In Brief Trial Updates…Length not stated
- full articlen editor and author. Original articles. Full articles should generally be no longer than 4500 words, excluding manuscript heading, abstract, acknowledgements,main text ≤ 4,500 words
- in brief trial updatesAnnals of Oncology publishes material in the form of Editorials, Original Articles, Letters to the Editor, Reviews, Special Articles, and In Brief Trial Updates…Length not stated
- letters to the editorAnnals of Oncology publishes material in the form of Editorials, Original Articles, Letters to the Editor, Reviews, Special Articles, and In Brief Trial Updates…Length not stated
- original articlesAnnals of Oncology publishes material in the form of Editorials, Original Articles, Letters to the Editor, Reviews, Special Articles, and In Brief Trial Updates…Length not stated
- reviewng and identified as such in the title. Review manuscripts summarize the state-of-the-art in a particular field and should be no longer than 5000 words excludin…main text ≤ 5,000 words
- reviewsAnnals of Oncology publishes material in the form of Editorials, Original Articles, Letters to the Editor, Reviews, Special Articles, and In Brief Trial Updates…Length not stated
- special articlesAnnals of Oncology publishes material in the form of Editorials, Original Articles, Letters to the Editor, Reviews, Special Articles, and In Brief Trial Updates…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Preprints
- AI use Declaration of generative AI in scientific writing
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. AI and AI-assisted technologies should not be used t…
Source ↗Publisher website ·- Authorship Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, …
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Data availability
Real-world data studies should be reported according to the ESMO-Guidance for Reporting Oncology Real-World evidence (GROW), with GROW checklist and flowchart provided at submission. Model summary
Real-world data studies should be reported according to the ESMO-Guidance for Reporting Oncology Real-World evidence (GROW). At manuscript submission, authors should provide the GROW checklist accompanied by a flowchart.
Source ↗Publisher website ·- License & copyright Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.Subscribers may reproduce tables of contents or prepare lists of articles includ…
Source ↗Publisher website ·- Open access Open access
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Preprints Preprints
Preprints can be shared anywhere at any time, in line with Elsevier's sharing policy; sharing preprints will not count as prior publication. Model summary
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Oxford University Press
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1990
- ISSN
- 0923-7534
- Electronic ISSN
- 1569-8041
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Annals of Oncology
What CAS zone is Annals of Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Annals of Oncology is in Zone 1 of Medicine, and in Zone 1 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Annals of Oncology?
The latest impact factor listed by LetPub is 76.9; CiteScore 69.6, h-index 390.
How long does peer review take at Annals of Oncology?
Based on the dates recorded on 87 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 79 days (interquartile range 35–155 days); authors report an average review time of 2–3 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Annals of Oncology?
According to the journal's author guidelines: Abstract: ≤ 300 words; Suggested reviewers: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Annals of Oncology based?
Of the 135 board members whose country the journal's board page names, 1 (about 1%) are in mainland China; the countries named most often are United States (26), Japan (23) and Italy (16). Counted from the institutions listed on the board page; for reference only.
Which databases index Annals of Oncology?
According to LetPub and DOAJ records, Annals of Oncology is indexed in SCIE and Scopus.
Is Annals of Oncology open access, and what is the APC?
Annals of Oncology is a hybrid journal. For open-access publication: APC about USD 5,080.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .